Bodybon Tablet (Bazedoxifene Acetate, Concentrated Powder of Cholecalciferol)

Adult dose

1 tablet once daily, taken regardless of meals.

This medication may increase the risk of venous thromboembolism and is not recommended for women at high risk of thrombosis. In particular, if movement is restricted, this medication should be discontinued and restarted only when mobility is fully regained. This medication should only be used by postmenopausal women, as safety has not been established in premenopausal women. While it does not induce endometrial hyperplasia, any occurrence of uterine bleeding must be reviewed by a specialist. It is not recommended to use this medication for prevention or treatment in patients with breast cancer. Women with hypersensitivity to this medication or its components, those with a history of thromboembolism, pregnant women, or nursing mothers should not use it. Additionally, patients with unexplained uterine bleeding, symptoms of endometrial cancer, lactose intolerance, hypercalcemia, or kidney stones should avoid it. Caution is required in patients with hypertriglyceridemia, renal or hepatic impairment, and those with restricted mobility, thus consultation with a physician is necessary. This medication may cause drowsiness or visual disturbances, so caution is advised during driving or operating machinery. If calcium intake is insufficient, additional supplements should be taken, and patients at high risk of vitamin D deficiency may require extra supplementation. Some medications can affect the metabolism of this medication, so it is essential to inform the physician of all medications being taken. Women who are pregnant or nursing should not take this medication, and if pregnancy is confirmed while taking it, it must be discontinued immediately. This medication is not intended for pediatric use, and while elderly patients do not require special dosage adjustments, caution is advised. In case of overdose, no specific antidote exists, so treatment must be symptomatic, and monitoring of blood calcium levels is necessary due to potential hypercalcemia in case of vitamin D overdose. This medication should be kept out of reach of children and stored in its original container.

Serious side effects

• Hives
• deep vein thrombosis
• pulmonary embolism
• retinal vein thrombosis
• chest tightness
• retinal hemorrhage
• vasodilation (facial flushing)
• dyspnea
• respiratory failure
• systemic edema

Mild side effects

• Drowsiness
• facial flushing
• leg cramps
• dry mouth
• rash
• itching
• muscle cramps
• peripheral edema
• elevated triglycerides in the blood
• increased alanine aminotransferase

This medication must be stored in a tightly sealed container to avoid exposure to air or humidity. It is important to maintain storage temperatures between 1 and 30 degrees Celsius.

Appearance

Yellow, biconvex, rectangular film-coated tablet

Package unit

30 tablets (10 tablets/PTP x 3)